Hanmi Pharmaceutical Exports 'Ensacvida' Technology to Gilead in $34.5 Million Deal

On September 29, Hanmi Pharmaceutical announced that it has signed a technology transfer agreement with Gilead Sciences and HealthHope Pharma (hereafter HHP), granting Gilead exclusive rights for the global development and commercialization of Ensacvida.

The total value of the upfront payment and milestone technology fees is 34.5 million dollars (approximately 4.83 billion won). The non-refundable upfront payment amounts to 2.5 million dollars (about 350 million won), and the milestone technology fees can reach up to 32 million dollars (about 4.48 billion won).

Orascovery, Hanmi Pharmaceutical’s independently developed platform technology, is an innovative drug delivery system that enables the conversion of injectable drugs into oral formulations. Ensacvida is a novel drug candidate discovered and initially developed by Hanmi using Orascovery.

Under this agreement, Hanmi Pharmaceutical and HHP will grant Gilead exclusive rights to Ensacvida in the antiviral field. Both companies plan to participate as key partners in the project by supplying Ensacvida’s active pharmaceutical ingredients (API) and finished products, as well as sharing technical know-how.

Hanmi Pharmaceutical and HHP will receive the upfront payment and milestone technology fees according to the stages of development, approval, and sales. They will also separately receive royalties (running royalties) based on future product sales.

This content was produced with the assistance of AI translation services.